Spun out of research at the University of Basel, the technology aims to improve therapies for rare genetic conditions such as Pompe disease (a rare genetic disorder that affects how the body breaks down glycogen, leading to progressive muscle damage) by increasing therapeutic activity in affected tissues.
NanoZymeX has raised €164k across 1 funding round from 1 investor, most recently a round in Mar 2026. Based in Basel, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-03-24 | Other | €164k |
| Venture Kick |
| View deal → |
